第5回 HTS之活性篩選法
5月12日(一)∼13日(二)
3D CELL CULTURE
Warming up a Cold Idea: Frozen Cells as Reagents for Automated 3D Cell Culture
Robin Felder, Ph.D., Professor, Pathology, University of Virginia
3-D Tissue Cultures for Safety and Efficacy Assessment of New Drug Candidates
Dawn R. Applegate, Ph.D., President & CEO, RegeneMed, Inc.
LABEL-FREE SCREENING
Duration, Duration, Duration: Optimizing Ligand-Receptor Kinetics in Drug Discovery
Mark Dowling, Ph.D., Research Investigator, Discovery Biology, Novartis
Application of Epic System in Cell-Based Assays
Hong Xin, Ph.D., Senior Scientist, Lead Generation, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CASE STUDIES
Lessons Learned from HTS Signaling Pathway Analysis in Cell-Based Assays to Advance Drug Discovery Programs for Lead Optimization Ge Zhang, Ph.D., Senior Research Investigator, Lead Evaluation, Bristol-Myers Squibb Co.
Integration of Complex Cell-Based Assays with Miniaturized HTS
Andrew Napper, Ph.D., Director, High-Throughput Screening, Penn Center for Molecular Discovery, University of Pennsylvania, As part of the Molecular Libraries Screening Center
NOVEL ASSAYS
Building Assays for Disease-Relevant Targets and their Mutants in Native Cell Backgrounds
Zhong Zhong, Ph.D., Director, R&D, Invitrogen Discovery Sciences
CELLS AS REAGENTS
Cryo-Preserved PBMC as Standardized Reagents for High-Throughput Clinical Testing
Thomas Kleen, Ph.D., Director, Assay Development, Immunology, Cellular Technology Ltd.
Title to Be Announced
Alison Rush, Ph.D., Senior Research Associate, Automated Biotechnology, Merck & Co., Inc.
Quantification of Neutralizing Antibodies to Interferons Using a Novel Cell-Based Assay
Michael Tovey, Ph.D., Director, Laboratory of Viral Oncology, Institute Andre Lwoff
BREAKOUT DISCUSSION
Label Free Tools in Drug Discovery: Where is their place in drug discovery?
Lisa K. Minor, Ph.D., Principal Scientist, Drug Discovery Research, Johnson & Johnson Pharmaceutical R&D
RECOMMENDED SHORT COURSE *Separate Registration Required
(SC2) 細胞培養之進展 (5月11日 2:00pm - 5:00pm)
In this short course, the faculty will highlight the number of industries that depend on cell culture and include how each can benefit from the 3D paradigm. For example, high-throughput screening and cell-based assay groups will be able to test compounds within more relevant cells. Public health officials and biomanufacturers will be able to respond more rapidly and regionally prior to potential pandemics. Furthermore, the discovery and production of humanized biotech drugs will benefit from a standard and scalable 3D cell culture process. New media formulations will provide the added nutritional support and buffering required for high production cell culture systems. Media design for small scale and manufacturing processes will also be featured.
